Co, Mary Dawn T.Terajima, MasanoriCruz, JohnEnnis, Francis A.Rothman, Alan L.2022-08-232022-08-232002-02-012017-08-30Virology. 2002 Feb 1;293(1):151-63. doi:10.1006/viro.2001.1255 <a href="https://doi.org/10.1006/viro.2001.1255">Link to article on publisher's site</a>0042-6822 (Linking)10.1006/viro.2001.125511853408https://hdl.handle.net/20.500.14038/35071Yellow fever virus (YFV) is a re-emerging problem despite the existence of an effective live-attenuated vaccine. The induction of YFV-neutralizing antibodies undoubtedly contributes to vaccine efficacy, but T lymphocyte responses to YFV likely play a role in long-term efficacy. We studied the T lymphocyte responses to YFV in four vaccinees. Proliferation and cytolytic responses to YFV were demonstrated in all subjects. We isolated 13 YFV-specific CD8(+) CTL lines that recognized epitopes on the E, NS1, NS2b, and NS3 proteins; eight CTL lines were HLA-B35-restricted. YFV-specific T cell responses were detectable by IFN gamma ELISPOT assays 14 days postvaccination, with T cell frequencies sustained for up to 19 months. To our knowledge, this is the first report of human T lymphocyte responses following YFV vaccination. These results indicate that the live 17D YFV vaccine induced CD8(+) T cell responses directed against at least four different HLA-B35-restricted YFV epitopes.en-USImmunityImmunology and Infectious DiseaseImmunology of Infectious DiseaseInfectious DiseaseVirologyJournal Articlehttps://escholarship.umassmed.edu/infdis_pp/28310680681infdis_pp/283